Last reviewed · How we verify
NCT06433622
Platelet Transfusion and Repeat Thromboelastography With Platelet Mapping (TEG-PM) in Patients With Severe Traumatic Brain Injuries (TBI) on Antiplatelet Therapy
trial testing Repeat Thromboelastography with Platelet Mapping in Traumatic Intracranial Hemorrhage in 225 participants. Enrolling by invitation.
1 December 2026
Quick facts
| Lead sponsor | Lancaster General Hospital |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 225 |
| Start date | 1 December 2023 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 November 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Repeat Thromboelastography with Platelet Mapping
Conditions studied
- Traumatic Intracranial Hemorrhage — all drugs for Traumatic Intracranial Hemorrhage →
Sponsor
Lancaster General Hospital
Who can join
18 and older, any sex, with Traumatic Intracranial Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Repeat TEG
Time frame: 1 hour after platelets given
Rate of reversed pathway inhibition on repeat thromboelastography with platelet mapping (TEG-PM) when platelets are administered to TICH patients who are on antiplatelet therapy prior to admission. -
Repeat Head CT
Time frame: From the time of interventional platelet administration until the time of patient discharge from their index admission, assessed up to 100 weeks.
Number of patients with improved platelet function on repeat TEG-PM and stability of TICH on subsequent CT scan.
Sponsor's own description
The aim of this study is to see if administering platelets (cells in our blood that stop or prevent bleeding) results in improved platelet function and slows/stops the progression of a head bleed for patients who have a traumatic head bleed and are on antiplatelet therapy (medications that stop blood cells from forming a blood clot) prior to admission.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06433622
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Lancaster General Hospital trials
Trials by the same sponsor.
- NCT05223751 — Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure · NA · terminated
- NCT04759066 — The HEALiX™ Intubated Patient (IP) Pilot Study · NA · withdrawn
- NCT04478773 — Adverse Events of MRI With Abandoned Leads · NA · terminated
- NCT04530539 — The Effect of Melatonin and Vitamin C on COVID-19 · NA · completed
- NCT04226365 — Pediatric Concussion Outcomes · Phase 4 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06433622 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lancaster General Hospital
- Last refreshed: 27 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06433622.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing